Leucovorin's Off-Label Use for Autism Traits Expands Amid Evidence Gaps

Understanding Off-Label Use and Folate's Role

Leucovorin, a synthetic form of folate, is FDA-approved only for cerebral folate deficiency (CFD) — a rare condition where folate transport to the brain is impaired. However, prescriptions for autistic individuals without CFD have increased, driven by reports of improved communication. Off-label use means prescribing a drug for conditions beyond its approved indications, a common but legally complex practice. For example, a 2026 Frontiers in Pharmacology review notes that 64% of autism-related prescriptions are off-label, typically for co-occurring conditions like anxiety.

Evaluating the Evidence

While small studies suggest leucovorin might help some autistic individuals with language delays, larger trials show inconsistent results. An ongoing clinical trial (NCT02839915) found that only 28% of participants showed measurable language improvement after six months, with no significant group-wide effects. Preclinical research, such as zebrafish studies at Yale, identified folate's role in neural development but hasn't translated to proven human therapies. As the FDA reiterated in March 2026, leucovorin lacks approval for general autism use due to insufficient evidence.

For example, a 2026 Frontiers in Pharmacology review notes that 64% of autism-related prescriptions are off-label, typically for co-occurring conditions like anxiety.

Risks and Realities of Off-Label Prescribing

Off-label use carries potential risks: leucovorin can cause nausea, sleep disturbances, and — in rare cases — allergic reactions. More critically, it might delay access to evidence-based supports like speech therapy. A 2025 Nature review found that behavioral interventions remain the most consistently effective approach for communication differences in autism. The rise in prescriptions also reflects systemic gaps; many families face long waits for therapies, as noted in a Bioengineer.org analysis of autism service disparities.

Toward Precision Approaches

Research is exploring whether leucovorin could benefit autistic subgroups with folate metabolism differences. A 2026 Cureus review highlights the need for biomarker-guided treatments rather than broad applications. Until such tools exist, clinicians and families must weigh leucovorin's unproven benefits against known risks and prioritize interventions with stronger evidence bases.